Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab.

IF 3.4 2区医学 Q2 RHEUMATOLOGY

Therapeutic Advances in Musculoskeletal Disease Pub Date : 2025-06-06 eCollection Date: 2025-01-01 DOI:10.1177/1759720X251340255

Jan Brandt-Jürgens, Martin Rudwaleit, Frank Behrens, Christopher Ritchlin, Daniel Peterlik, Erhard Quebe-Fehling, Atul Deodhar

{"title":"Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab.","authors":"Jan Brandt-Jürgens, Martin Rudwaleit, Frank Behrens, Christopher Ritchlin, Daniel Peterlik, Erhard Quebe-Fehling, Atul Deodhar","doi":"10.1177/1759720X251340255","DOIUrl":null,"url":null,"abstract":"Background: The incidence rate of uveitis in secukinumab-treated patients with axial spondyloarthritis (axSpA) was previously reported.Objective: To evaluate the incidence rate of uveitis in patients with axSpA and psoriatic arthritis (PsA) treated with secukinumab or placebo during placebo-controlled phase III studies.Design: This was a post hoc analysis from 11 phase III studies.Methods: Pooled data from axSpA (MEASURE 1-5 and PREVENT studies) and PsA (FUTURE 1-5 studies) were analyzed.Results: In the axSpA cohort (N = 1980), the incidence rate for uveitis was 1.29 per 100 patient-years in the secukinumab 150 mg and 1.72 per 100 patient-years in the placebo arm. In the PsA cohort (N = 2453), the incidence rate for uveitis was 0.71 per 100 patient-years in the secukinumab 300 mg arm; no events were reported in the placebo arm.Conclusion: During the placebo-controlled phase, a numerically lower incidence of uveitis was observed in secukinumab-treated axSpA patients. In PsA patients, the incidence was low in secukinumab-treated patients, while uveitis was not reported in the placebo group.","PeriodicalId":23056,"journal":{"name":"Therapeutic Advances in Musculoskeletal Disease","volume":"17 ","pages":"1759720X251340255"},"PeriodicalIF":3.4000,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144362/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Musculoskeletal Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1759720X251340255","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The incidence rate of uveitis in secukinumab-treated patients with axial spondyloarthritis (axSpA) was previously reported.

Objective: To evaluate the incidence rate of uveitis in patients with axSpA and psoriatic arthritis (PsA) treated with secukinumab or placebo during placebo-controlled phase III studies.

Design: This was a post hoc analysis from 11 phase III studies.

Methods: Pooled data from axSpA (MEASURE 1-5 and PREVENT studies) and PsA (FUTURE 1-5 studies) were analyzed.

Results: In the axSpA cohort (N = 1980), the incidence rate for uveitis was 1.29 per 100 patient-years in the secukinumab 150 mg and 1.72 per 100 patient-years in the placebo arm. In the PsA cohort (N = 2453), the incidence rate for uveitis was 0.71 per 100 patient-years in the secukinumab 300 mg arm; no events were reported in the placebo arm.

Conclusion: During the placebo-controlled phase, a numerically lower incidence of uveitis was observed in secukinumab-treated axSpA patients. In PsA patients, the incidence was low in secukinumab-treated patients, while uveitis was not reported in the placebo group.

查看原文本刊更多论文

轴性脊柱炎或银屑病关节炎患者的葡萄膜炎：一项使用secukinumab的安慰剂对照III期研究的事后分析

背景：以前曾报道过secukinumumab治疗的轴性脊柱炎（axSpA）患者的葡萄膜炎发病率。目的：评估在安慰剂对照III期研究中，接受secukinumab或安慰剂治疗的axSpA合并银屑病关节炎（PsA）患者葡萄膜炎的发生率。设计：这是一项来自11项III期研究的事后分析。方法：对axSpA （MEASURE 1-5和prevention研究）和PsA （FUTURE 1-5研究）的汇总数据进行分析。结果：在axSpA队列（N = 1980）中，secukinumab 150 mg组的葡萄膜炎发病率为1.29 / 100患者-年，安慰剂组为1.72 / 100患者-年。在PsA队列中（N = 2453），在secukinumab 300 mg组中，葡萄膜炎的发病率为0.71 / 100患者-年；在安慰剂组中未报告任何事件。结论：在安慰剂对照期，使用secukinumumab治疗的axSpA患者的葡萄膜炎发生率较低。在PsA患者中，接受secukinumab治疗的患者发病率较低，而安慰剂组未报告葡萄膜炎。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Musculoskeletal Disease Medicine-Rheumatology

CiteScore

6.80

自引率

4.80%

发文量

132

审稿时长

18 weeks

期刊介绍： Therapeutic Advances in Musculoskeletal Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of musculoskeletal disease.